🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccination schedules, one figure appears somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 shots during the pandemic and has focused upon potential deaths following Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Program

Public health authorities had intended to announce sweeping changes to the pediatric vaccination calendar recently, bringing the US with the Danish national calendar, sources say – a major change that would put the US at odds with a large portion of the global community with little proof for public health gain. The announcement has been delayed until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to run the center this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for halting specific childhood shot schedules in the US in order to be more like Denmark, a nation with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – traditionally the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Høeg has no obvious experience in medication creation, oversight or management, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She lacks background in industry regulation.”

Past commissioners of the center would “be deeply familiar with legal statutes and the research of drug development”, noted a former acting FDA commissioner. “Clearly, she lacks the kind of background that previous people who ran the center have had.”

This division has an immense portfolio at the FDA, she stated.

“Many people just focuses on the innovative therapies, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and all of those need to be looked after,” Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the job, which oversees more than 5,000 employees. “It’s a massive management job, if you execute it properly,” she said.

Official Statement and Controversial Initiatives

In response to concerns about Høeg’s qualifications and whether this appointment signifies more teamwork among agency officials on vaccines, a spokesperson responded that the “questions are based on incorrect presumptions”.

“Her experience matches the functions of her job,” the spokesperson explained, noting the period Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial expedited drug-approval program that reportedly worried her predecessors. “By what process are these therapies being selected for this voucher program? Who is making the calls?” Dr. Howard said. “There is a lot of secrecy going on at the agency right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards less stringent oversight of pharmaceuticals, except for shots.”

Established Track Record on Immunizations

Regarding vaccines, Høeg has a more established, if concerning, past, critics observe. She published a research paper using unverified volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the current federal leadership featured altering regulations for recently developed shots and halting “non-essential” immunizations, she said after the election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of barring teenage boys from receiving COVID-19 vaccines.

“She’s an all-around true believer who commences with her beliefs and reverse-engineers to fit the evidence in a highly misleading, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|